Metastatic Esophageal Carcinoma

Two late-breaking abstracts highlight tislelizumab plus chemotherapy combination strategy in solid tumors with high unmet need Additional presentations showcase potential of biology-driven tislelizumab combination approaches with BeiGene pipeline molecules BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of promising new data showcasing BeiGene’s robust, science-driven solid tumor portfolio of commercialized and pipeline medicines at the European Society for Medical Oncology (ESMO) Congress 2023. Highlights include the presentations of two late-breaking abstracts for tislelizumab, an anti-PD-1 antibody and the first medicine to emerge from BeiGene’s immuno-oncology biologics program: Final analysis from the global, Phase 3 RATIONALE-305 study (NCT03777657) evaluating tislelizumab plus chemotherapy as a first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) Final analysis of pathological response to neoadjuvant tislelizumab plus chemotherapy in patients with resectable Stage II-IIIA non-small cell lung cancer (NSCLC) in results from the Phase 3 RATIONALE-315 study (NCT04379635) “At ESMO 2023, we look forward to presenting results from several clinical trials of tislelizumab in combination with other therapies across multiple disease areas and lines of treatment,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “Tislelizumab is the cornerstone of BeiGene’s diverse pipeline of pan-solid tumor programs for the next wave of immuno-oncology targets. We are delighted to have recently regained the global rights to this important medicine and remain dedicated to following the science and data to advance new combination strategies for the treatment of solid tumors.” TEVIMBRA® (tislelizumab) was recently approved in the European Union (EU) as monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior platinum-based chemotherapy. Additionally, the U.S. Food and Drug Administration (FDA) recently accepted for review a Biologics License Application for tislelizumab as a first-line treatment for patients with unresectable, recurrent, locally advanced, or metastatic ESCC. More details on BeiGene’s abstracts are available in the ESMO Programme. Presentations of Company-Sponsored Trials Tislelizumab Tislelizumab (TIS) Plus Chemotherapy (Chemo) vs Placebo (PBO) Plus Chemo as First-Line (1L) Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GC/GEJC): Final Analysis Results of the RATIONALE-305 Study (Abstract #LBA80) Mini oral presentation, Saturday, October 21, 5:25-5:30 PM CEST Pathological Response to Neoadjuvant Tislelizumab (TIS) Plus Platinum-Doublet (PtDb) Chemotherapy (CT) in Resectable Stage II-IIIA NSCLC Patients (pts) in the Phase 3 (Ph3) RATIONALE-315 Trial (Abstract #LBA58) Mini oral presentation, Monday, October 23, 2:55-3:00 PM CEST Randomized, Global, Phase 3 Study of Tislelizumab (tis) + Chemotherapy (chemo) vs Placebo (PBO) + Chemo as First-line (1L) Treatment for Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC): RATIONALE-306 Study Update (Abstract #1514P) Poster presentation, Monday, October 23 Long-term Follow-up of a Phase 2 Study of Tislelizumab (TIS) Monotherapy in Patients (pts) With Previously Treated, Locally Advanced, Unresectable or Metastatic Microsatellite Instability-high (MSI-H) or Mismatch Repair-deficient (dMMR) Solid Tumors. BGB-A317-209 Study (Abstract #1057P) Poster presentation, Monday, October 23 Ociperlimab Development Program AdvanTIG-203: Phase 2 Randomized, Multicenter Study of Ociperlimab (OCI) + Tislelizumab (TIS) in Patients (pts) With Unresectable, Locally Advanced, Recurrent/Metastatic Esophageal Squamous Cell Carcinoma (ESCC) and Programmed Cell Death-Ligand 1 (PDL1) Positivity (Abstract #1020MO) Mini oral presentation, Saturday, October 21, 4:30-4:35 PM CEST AdvanTIG-206: Phase 2 randomized open-label study of ociperlimab (oci) + tislelizumab (tis) + BAT1706 (bevacizumab biosimilar) versus tis + BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC) (Abstract #945MO) Mini oral presentation, Saturday, October 21, 4:30-4:35 PM CEST AdvanTIG-202: Phase 2 Randomized, Multicenter, Open-Label Study of Tislelizumab (tis) With or Without Ociperlimab (oci) in Patients (pts) With Previously Treated Recurrent/Metastatic (R/M) Cervical Cancer (CC) (Abstract #744MO) Mini oral presentation, Sunday, October 22, 10:55-11:00 AM CEST AdvanTIG-105: Phase 1b Dose-expansion Study of Ociperlimab (OCI) + Tislelizumab (TIS) with Chemotherapy (CT) in Patients (pts) with Metastatic Esophageal Squamous Cell Carcinoma (ESCC) and Esophageal Adenocarcinoma (EAC) (Abstract #1533P) Poster presentation, Monday, October 23 Additional Pipeline Assets Zanidatamab (zani) Plus Chemotherapy (chemo) and Tislelizumab (tis) as First-line (1L) Therapy for Patients (pts) With Advanced HER2-positive (+) Gastric/Gastroesophageal Junction Adenocarcinoma (GC/GEJC): Updated Results From a Phase 1b/2 Study (Abstract #1518P) Poster presentation, Monday, October 23 Phase (Ph) 1/2 Study of Sitravatinib (sitra) Alone or With Tislelizumab (tis) in Advanced Hepatocellular Carcinoma (HCC) and Gastric/Gastroesophageal Junction Cancer (GC/GEJC) (Abstract #948P) Poster presentation, Monday, October 23 About Tislelizumab Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody, with high affinity and binding specificity against PD-1, specifically designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping to aid the body’s immune cells to detect and fight tumors. In pre-clinical studies, binding to Fcγ receptors on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.i,ii,iii,iv The tislelizumab development program encompasses 21 registration-enabling clinical trials in more than 30 countries and regions. To date, BeiGene has announced positive readouts from 10 Phase 3 pivotal studies across multiple tumor types and disease settings, such as NSCLC, small cell lung cancer, gastric cancer, ESCC, hepatocellular cancer, and nasopharyngeal cancer. More information on the clinical trial program for tislelizumab can be found at: . Tislelizumab is currently under review by the FDA and received approval by the European Commission for advanced or metastatic ESCC after prior chemotherapy. Additionally, the FDA recently accepted for review a Biologics License Application for tislelizumab as a first-line treatment for patients with unresectable, recurrent, locally advanced, or metastatic ESCC. The EMA is reviewing a marketing authorization application for tislelizumab as a treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy, and in combination with chemotherapy for previously untreated locally advanced or metastatic NSCLC. Regulatory submissions for tislelizumab are also under review by authorities in Australia, Brazil, China, Korea, Israel, New Zealand, Singapore, Switzerland, and the U.K. Tislelizumab is approved as a treatment in 11 indications in China and is the leading PD-1 inhibitor in the country. About BeiGene BeiGene is a global biotechnology company that is discovering and developing innovative oncology treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents, with administrative offices in Basel, Beijing, Cambridge, and U.S. To learn more about BeiGene, please visit and follow us on LinkedIn and X (formerly known as Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s advancement, anticipated clinical development, regulatory milestones and commercialization of tislelizumab, ociperlimab and other pipeline assets; BeiGene’s ability to advance new combination strategies for the treatment of solid tumors; the general future of BeiGene’s pipeline and programs; and BeiGene’s plans, commitments, aspirations, and goals under the heading “About BeiGene.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law. i Desai J et al. Ann Oncol. 2017;28(suppl_5):v122–v141. ii Zhang T et al. Cancer Immunol Immunother. 2018;67:1079–1090. iii Arlauckas SP et al. Sci Transl Med. 2017;9:eaal3604. iv Dahan R et al. Cancer Cell. 2015;28:285–295. View source version on businesswire.com: Contacts Investor Contact: Liza Heapes +1 857-302-5663 ir@beigene.com EU Media Maryline Iva +41 61 685 2090 media@beigene.com Source: BeiGene, Ltd. View this news release online at:

SEATTLE--(BUSINESS WIRE)-- Dr. Ching-Hon Pui, Co-Leader, Hematological Malignancies Program, St. Jude, Memphis, TN and 2020 American Cancer Society Medal of Honor Awardee, “I am very impressed with your previous efforts to help my former patient. You provided AVM0703 in a record time (less than 24 hours) to my patient by sending your colleague by plane to hand deliver the medication to St. Jude from Seattle, WA. The drug yielded an amazing response. Even though my patient had very advanced leukemia, AVM0703 helped to control the disease and bridged him to CAR T cells therapy.” This press release features multimedia. View the full release here: A metastatic esophageal adenocarcinoma patient during his 8th AVM0703 infusion. "Overall I have to say AVM0703 has been the only drug used to tackle my throat cancer since my first AVM0703 treatment on Nov 18th Nov 2022. The result has been rewarding with little by way of side effects apart from dull pain emerging 24 hours after treatment periods round cancer infected upper chest area. This pain seems to last approx 3 hours then fades away and sometimes repeats again on the second day after treatment. No doubt this pain is AVM0703 at work, targeting the cancer. Thank you all for your advice and guidance, by putting the wellness back into my health again. Thank you to all at AVM Biotechnology." (Photo: Business Wire) AVM Biotechnology, a clinical stage company actively enrolling Phase 2 for Relapsed/Refractory Non-Hodgkin’s Lymphoma of all subtypes (partially funded by NCI Ph II FastTrak grant 1R44CA272096), today announced that twenty-eight (28) solid tumor and blood cancer patients have been treated with its immunomodulatory drug AVM0703 through Expanded Access (EAP)/Compassionate Use (CUP) programs. Cancers that have been treated include highly relapsed/refractory, some imminently terminal, patients with glioblastoma, metastatic breast cancer (two with advanced bone metastases), metastatic ovarian cancer, metastatic gastric cancer, Hodgkin’s Lymphoma, mixed phenotype acute leukemia, B-ALL, metastatic colon cancer, malignant myxoid spindle cell neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, desmoplastic small round cell tumor, metastatic esophageal adenocarcinoma, prostate cancer, anaplastic T-cell Non-Hodgkin’s Lymphoma and inoperable/chemotherapy ineligible CNS squamous cell carcinoma. Immunomodulatory AVM0703's relatively broad anti-cancer activity is hypothesized to be due to mobilization of a highly active gamma/delta T-cell receptor expressing immune cell, which is programmed to recognize special stress signals produced by most cancer cells but not normal cells. Requests for additional information about immunomodulatory AVM0703 and its relatively broad activity against solid tumors and blood cancers can be made by contacting compassionateuse@avmbiotech.com. “AVM Biotechnology is committed to providing AVM0703 to patients who cannot participate in our enrolling clinical trial. Based on absence of safety concerns and responses reported to date, we believe AVM0703 may provide benefits to all cancer patients who are desperately searching for options. Our team at AVM Biotechnology is dedicated to providing hope to patients and their loved ones.” Theresa Deisher, AVM Biotechnology, Founder and CEO. Requests for Expanded Access in the US must be made by a US licensed physician. Physicians can learn more about the AVM0703 EAP on clinicaltrials.gov and can request access by sending an email to compassionateuse@avmbiotech.com. About AVM0703: AVM0703 is small molecule immunomodulatory drug enrolling Phase 2 trials in US in relapsed/refractory Non-Hodgkin's Lymphoma (NHL) which began enrollment Q3 2023 (partially funded by NCI Ph II FastTrak grant 1R44CA272096). AVM0703 mobilizes a novel endogenous bispecific gamma delta TCR+ invariant TCR+ Natural Killer T-like cell with profound antitumor activity. AVM0703 has shown an absence of safety concerns with side-effects limited to grades 1-3. Clinical responses in the enrolling NHL trial and in FDA-approved expanded access/compassionate use include multiple NHL sub-types and diverse solid tumor types. Responses to AVM0703 are quite rapid, reported from 30 minutes to 14 days after infusion. Preclinical data also demonstrates a significant response against autoreactive lymphocytes in the NOD Type 1 diabetes model (Funded by NIDDK SBIR Ph I grant 1R43DK121634 and NIDDK SBIR Ph II grant 2R44DK121634). Gamma delta TCR+ lymphocytes recognize phosphoantigens expressed by stressed, cancer and infected cells and autoreactive lymphocytes, but not normal cells. Adoptive transfer of AVM0703 induced gamma delta TCR+ immune cells has potent activity against preclinical melanoma (funded by NCI SBIR Ph I grant 1R43CA246896). Additionally, AVM0703 has been shown to have potent neo-adjuvant activity before chemotherapy against immune-resistant, aggressive mouse A20 lymphoma (Funded by NCI SBIR Ph I 1R43_CA271951). Based on its ability to penetrate collagen-encased desmoplastic tumors, AVM0703 has promise as a neoadjuvant prior to chemoimmunotherapy to improve outcomes for metastatic advanced pancreatic cancer patients. About AVM Biotechnology Inc: AVM Biotechnology is a clinical stage company headquartered in Seattle, WA developing immunomodulatory therapies for hematological cancer, infectious and autoimmune diseases. AVM’s pipeline includes a small molecule that triggers blood cell formation to replace transfusions, and an allogeneic γδTCR+invTCR+ NKT-like cell. AVM Biotechnology has been selected after competitive review by the National Cancer Institute (NCI) as one of the showcase companies for the 2023-2024 National Cancer Institute Small Business Innovation Research (SBIR) Investor Initiatives. AVM Biotechnology has been awarded five (5) highly competitive National Institute of Health SBIR grants; 2 Phase 1 grants and 1 Phase 2 grant from NCI, and 1 Phase 1 and 1 Phase 2 grant from NIDDK to prevent and reverse type 1 diabetes. About US Expanded Access Programs: Sometimes called "compassionate use", expanded access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. Expanded access may be appropriate when all the following apply: Patient has a serious or immediately life-threatening disease or condition. There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition. Patient enrollment in a clinical trial is not possible. Potential patient benefit justifies the potential risks of treatment. Providing the investigational medical product will not interfere with investigational trials that could support a medical product's development or marketing approval for the treatment indication. Investigational drugs, biologics or medical devices have not yet been approved or cleared by FDA and FDA has not found these products to be safe and effective for their specific use. Furthermore, the investigational medical product may, or may not, be effective in the treatment of the condition, and use of the product may cause unexpected serious side effects. About Compassionate Use Programs: In New Zealand, prescribers may be aware that Section 25 of the Medicines Act 1981 permits practitioners to procure for sale or supply any medicine for a particular patient in their care. In addition, Section 29 of the Medicines Act 1981 enables a New Zealand company to obtain and supply an unapproved medicine when authorised by a prescriber. It is the prescriber's responsibility to ensure that they remain cognisant of any safety issues relating to any unapproved medicines they may be prescribing and communicate the risks and benefits to their patients. Medsafe has a number of links on its website that healthcare professionals may find helpful. These links can be found at: Forward Looking Statements: This contains certain statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not relate strictly to historical or current facts and they may be accompanied by words such as "could," "would," "may," "potentially," "suggest," "believes," "expects," "should," and similar words or expressions. These forward-looking statements reflect our current views as of the date this is published, and are subject to risks, uncertainties, assumptions, changes in circumstances, and other factors; drug development and commercialization are highly risky and early clinical results in animals or humans may not reflect the full results from later stage or larger scale clinical trials. These forward-looking statements are subject to risks and uncertainties that could cause our actual results, performance, and expectations to differ materially from those expressed or implied by these statements, including statements about: future and ongoing drug development and timing; the applications of drugs to specific diseases; the potential for ongoing preclinical or clinical trial results; FDA or other regulatory findings and approvals; potential market opportunities; and the occurrence of future events or circumstances. There are risks and uncertainties involving and not limited to our ability to progress in our research and development efforts, complete clinical testing, achieve our expected results, commercialize our products, avoid infringement of patents, trademarks and other proprietary rights of third parties, protect products from competition, navigate the political environment, maintain sufficient capital and funding, avoid problems with our manufacturing processes, maintain our operations, and obtain regulatory approval to sell and market the drugs in the United States and elsewhere. The reader should not place any undue reliance on such forward-looking statements. We have no obligation to release publicly the results of any revisions to any of our forward-looking statements to reflect events or circumstances after the date these statements are made or to reflect the occurrence of unanticipated events, except as may be required by law. View source version on businesswire.com: Contacts AVM Biotechnology Theresa Deisher tdeisher@avmbiotech.com Compassionate Use Mia Lor mlor@avmbiotech.com Partnering/Investing Todd Bertsch tbertsch@avmbiotech.com Source: AVM Biotechnology Smart Multimedia Gallery Photo A metastatic esophageal adenocarcinoma patient during his 8th AVM0703 infusion. "Overall I have to say AVM0703 has been the only drug used to tackle my throat cancer since my first AVM0703 treatment on Nov 18th Nov 2022. The result has been rewarding with little by way of side effects apart from dull pain emerging 24 hours after treatment periods round cancer infected upper chest area. This pain seems to last approx 3 hours then fades away and sometimes repeats again on the second day after treatment. No doubt this pain is AVM0703 at work, targeting the cancer. Thank you all for your advice and guidance, by putting the wellness back into my health again. Thank you to all at AVM Biotechnology." (Photo: Business Wire) Logo View this news release and multimedia online at:

The dynamics of the esophageal cancer market are predicted to grow owing to the increasing prevalence of cancer and the increase in research & development. In addition, the anticipated launch of emerging therapies will also propel the esophageal cancer market growth in the coming years. LAS VEGAS, July 6, 2023 /PRNewswire/ -- DelveInsight's Esophageal Cancer Market Insights report includes a comprehensive understanding of current treatment practices, esophageal cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Key Takeaways from the Esophageal Cancer Market Report As per DelveInsight analysis, the esophageal cancer market size in the 7MM was approximately USD 1,000 million in 2022. According to the assessment done by DelveInsight, the estimated total diagnosed incident esophageal cancer cases in the US were approximately 20K in 2022. Globally, leading esophageal cancer companies such as Zymeworks, Innovent Biologics, BeiGene, Apexigen, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Symphogen, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences., Leap Therapeutics, Inc., Adlai Nortye Biopharma Co., Ltd., Athenex, Inc., Pfizer, Genentech, Hangzhou Neoantigen Therapeutics, Janssen Pharmaceutical, Curis, Inc., Merck KGaA, Shenzhen Hornetcorn Bio-technology Company, LTD, MacroGenics, Bristol-Myers Squibb, Integral Molecular, CARTEXELL, EMD Serono, and others are developing novel esophageal cancer drugs that can be available in the esophageal cancer market in the coming years. The promising esophageal cancer therapies in the pipeline include Zanidatamab, Sintilimab, Tislelizumab, Sotigalimab (APX005M), and others. Discover which therapies are expected to grab the major esophageal cancer market share @ Esophageal Cancer Market Report Esophageal Cancer Overview Esophageal cancer arises when cancer cells originate in the esophagus, a tube-like tissue that connects the throat and stomach. The esophagus transfers food from the mouth to the stomach. The cancer develops in the inner layer of the esophagus and can spread to other layers of the esophagus and other organs of the body. Typically, signs of esophageal cancer do not develop until the tumor has grown large enough to obstruct eating, swallowing, or digesting food. The most common symptom of esophageal cancer is difficulty swallowing, specifically a sense that food is trapped in the throat; in some cases, choking on food occurs. These symptoms worsen with time, with increasing discomfort while swallowing as the esophagus narrows due to cancer growth. Indications or symptoms of esophageal cancer are frequently used to diagnose it. Exams, testing, and a biopsy will be required to confirm the diagnosis; if cancer is found, additional tests will be performed to determine the extent. Esophageal Cancer Epidemiology Segmentation DelveInsight estimates that there were approximately 20K diagnosed incident cases of esophageal cancer in the US in 2022. In 2022, as per the age-specific cases, the 65 and above segment accounted for the highest number of cases of esophageal cancer. In contrast, the <45 age group accounted for the least number of cases in the United States. The esophageal cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Esophageal Cancer Diagnosed Incident Cases Esophageal Cancer Age-specific Cases Esophageal Cancer Histology-specific Cases Esophageal Cancer Gender-specific Cases Esophageal Cancer Mutation-specific Cases Esophageal Cancer Stage-specific Cases Esophageal Cancer Line-wise Treated Cases Esophageal Cancer Treatment Market Everyone with esophageal cancer is treated in some way. The best course of therapy for each patient is determined by a number of criteria, including personal preferences, cancer stage, and overall health. Many medical specialists work together on a daily basis in cancer care to create a patient's comprehensive treatment plan, which includes a variety of treatments. Esophagectomy is the primary esophageal cancer treatment for early-stage esophageal cancer, while its precise role in superficial (T1A) malignancies remains unknown, owing to the introduction of endoscopic mucosal therapy. A multimodal strategy of neoadjuvant chemotherapy or combination chemoradiotherapy (CRT) followed by surgery is strongly recommended for treating locally advanced malignancies. Preoperative evaluation is the cornerstone of modern esophageal cancer management. The precision and specificity of the clinical staging evaluation will be dependent on the tumor board's recommendations on the use of multimodal therapy, thus preoperative staging accuracy is crucial. The standardized evaluation of a patient undergoing curative treatment for early-stage or advanced esophageal cancer includes upper endoscopy, high-resolution contrast CT scan, FDG-PET scan, and EUS. For a tumor that has not migrated beyond the esophagus and lymph nodes, doctors often recommend a combination of radiation treatment, chemotherapy, and surgery. Locally advanced esophageal cancer is typically treated with radiation therapy, chemotherapy, and surgery. Radiation treatment and chemotherapy are frequently combined in "chemoradiotherapy." Radiation therapy, chemotherapy, and other drug-based therapies are frequently used to treat metastatic esophageal cancer. To know more about esophageal cancer treatment, visit @ Esophageal Cancer Treatment Drugs Key Esophageal Cancer Therapies and Companies Zanidatamab: Zymeworks Sintilimab: Innovent Biologics Tislelizumab: BeiGene Sotigalimab (APX005M): Apexigen Nivolumab: Bristol-Myers Squibb Pembrolizumab: Merck Sharp & Dohme Learn more about the FDA-approved drugs for esophageal cancer @ Drugs for Esophageal Cancer Treatment Esophageal Cancer Market Dynamics The esophageal cancer market is expected to change in the coming years owing to expanding disease awareness and increased healthcare spending around the world, which will increase the size of the esophageal cancer market. The esophageal cancer companies and academics are working to assess challenges and seek opportunities that could influence esophageal cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition. Esophageal cancer companies are involved in developing esophageal cancer therapies. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the esophageal cancer market in the 7MM. However, several factors are impeding the growth of the esophageal cancer market. The cost of newly approved drugs is typically exorbitant, so people avoid correct therapy or opt for off-label and low-priced medications. It has an impact on market access for newly released drugs, and reimbursement is critical. Market access and reimbursement options might vary depending on regulatory status, target population size, care environment, unmet requirements, the volume of extra benefit claims, and costs. Furthermore, the esophageal cancer market growth may be offset by failures and discontinuation of emerging therapies and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the esophageal cancer market growth. Scope of the Esophageal Cancer Market Report Therapeutic Assessment: Esophageal Cancer current marketed and emerging therapies Esophageal Cancer Market Dynamics: Attribute Analysis of Emerging Esophageal Cancer Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's Views, Analyst's Views, Esophageal Cancer Market Access and Reimbursement Discover more about esophageal cancer drugs in development @ Esophageal Cancer Clinical Trials Table of Contents Related Reports Esophageal Cancer Pipeline Esophageal Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key esophageal cancer companies, including BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc, Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., Adlai Nortye, Seagen, among others. Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) Market Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GEJ-NET companies, including Vedanta Biosciences, Inc., Bristol-Myers Squibb, Incyte Corporation, Xencor, Inc., ICON plc, Adaptimmune, Medicenna Therapeutics, Inc., Guangdong Zhongsheng Pharmaceutical Co., Ltd., among others. Esophageal Squamous Cell Carcinoma Pipeline Esophageal Squamous Cell Carcinoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key esophageal squamous cell carcinoma companies, including BeiGene, AstraZeneca, Ipsen, Shire, Sanofi, Seagen, among others. Esophageal Squamous Carcinoma Market Esophageal Squamous Carcinoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key esophageal squamous carcinoma companies, including BeiGene, AstraZeneca, Ipsen, Shire, Sanofi, Seagen, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Expand your knowledge and gain valuable insights into personalized cancer care through DelveInsight's Conference Coverage Services Explore some of the conference coverage related case studies: Conference Coverage in Various Oncology Conferences Conference Coverage Intelligence of Asthma and COPD assets across the Respiratory Therapy Area Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP